AVROBIO Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 91

Employees
  • Stock Symbol
  • AVRO

Stock Symbol
  • Share Price
  • $1.05

  • (As of Monday Closing)

AVROBIO General Information

Description

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.

Contact Information

Website
www.avrobio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 100 Technology Square
  • 6th Floor
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AVROBIO Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.05 $1.11 $0.56 - $1.93 $47.2M 44.1M 2.13M -$2.30

AVROBIO Financials Summary

In Thousands,
USD
TTM 31-Mar-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV (32,012) (69,556) (33,307) 358,280
Revenue 0 0 0 0
EBITDA (99,964) (104,151) (117,503) (119,224)
Net Income (101,014) (105,890) (119,126) (119,712)
Total Assets 83,005 103,949 203,837 271,234
Total Debt 18,335 16,463 14,945 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AVROBIO Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AVROBIO‘s full profile, request access.

Request a free trial

AVROBIO Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore AVROBIO‘s full profile, request access.

Request a free trial

AVROBIO Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentivira
Biotechnology
Cambridge, MA
91 As of 2023
00000
000000&0

000000

olor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pari
0000000000000
Cambridge, United Kingdom
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

000000

am, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo cons
0000000000000
Cambridge, MA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AVROBIO Competitors (57)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biosceptre Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000 00000
000000000000 Formerly VC-backed Mountain View, CA 000 00000 000000&0 00000
0000 000000 Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed Houston, TX 00 00000 00000000000 00000
You’re viewing 5 of 57 competitors. Get the full list »

AVROBIO Patents

AVROBIO Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4175717-A2 Compositions and methods for treating neurocognitive disorders Pending 02-Jul-2020 0000000000
CA-3127804-A1 Compositions and methods for treating neurocognitive disorders Pending 01-Feb-2019 0000000000
EP-3917623-A1 Compositions and methods for treating neurocognitive disorders Pending 01-Feb-2019 0000000000
US-20220133850-A1 Compositions and methods for treating neurocognitive disorders Pending 01-Feb-2019 0000000000
CA-3128003-A1 Compositions and methods for treating neurocognitive disorders Pending 01-Feb-2019 A61K38/18
To view AVROBIO’s complete patent history, request access »

AVROBIO Executive Team (21)

Name Title Board Seat Contact Info
Erik Ostrowski Chief Executive Officer & Chief Financial Officer, Finance
Geoff MacKay Co-Founder, Chief Executive Officer, President & Board Member
Azadeh Golipour Chief Technology Officer, Technology
Steven Avruch JD Chief Legal Officer
Christopher Mason MD Chief Scientific Officer & Founder
You’re viewing 5 of 21 executive team members. Get the full list »

AVROBIO Board Members (10)

Name Representing Role Since
Annalisa Jenkins MD Self Board Member 000 0000
Bruce Booth Ph.D Atlas Venture Chairman & Board Member 000 0000
Christopher Paige Ph.D AVROBIO Board Member 000 0000
Gail Farfel Ph.D Self Board Member 000 0000
Ian Clark AVROBIO Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

AVROBIO Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AVROBIO Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AVROBIO‘s full profile, request access.

Request a free trial

AVROBIO ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

27 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,480

Rank

00.0

Percentile

Pharmaceuticals

Industry

00 of 905

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 404

Rank

00.00

Percentile

To view AVROBIO’s complete esg history, request access »